PSK and OK-432-Induced Immunomodulation of Inducible Nitric Oxide (NO) Synthase Gene Expression in Mouse Peritoneal Polymorphonuclear Leukocytes and NO-Mediated Cytotoxicity

References

• Tsukagoshi S., Ohashi F. Protein bounds polysaccharide preparation, PSK, effective against mouse sarcoma-180 and rat ascites hepatoma AH-13 by oral use. Jpn. J. Cancer Res. 1974; 65: 557
   Google Scholar
• Watanabe Y., Takahasi I. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J. Biol. Response Modif. 1987; 6: 169
   PubMedGoogle Scholar
• Tsukagoshi S., Hashimoto Y., Fujii G. Krestin (PSK). Cancer Treat. Rev. 1984; 11: 131
   PubMed Web of Science ®Google Scholar
• Kariya Y., Okamoto N., Fujimoto T. Lysis of fresh human tumor cells by autologus peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK. Jpn. J. Cancer Res. 1991; 82: 1044
   PubMedGoogle Scholar
• Ryoyama K. Effector molecules from antitumor macrophages induced with OK-432 and cyclophosphamide. Cancer Immunol. Immunother. 1992; 35: 7
   PubMed Web of Science ®Google Scholar
• Akamatsu Y., Fuchimoto S., Orita K. The changing pattern of the splenic lymphocyte subsets in tumor-bearing mice after oral treatment with OK-432. Jpn. J. Cancer Res. 1992; 83: 656
   PubMedGoogle Scholar
• Ogoshi K. Evaluation of immunotherapy with PSK in esophageal cancer. Gan To Kagaku Ryoho 1988; 15: 3143
   PubMedGoogle Scholar
• Torisu M., Hayashi Y., Ishimatsu T. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol. Immunother. 1990; 31: 261
   PubMed Web of Science ®Google Scholar
• Nakazato H., Koike A., Saji S. Efficacy of immnochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994; 343: 1122
   PubMed Web of Science ®Google Scholar
• Ogoshi K., Miyaji M., Iwata K. Splenectomy, immunosuppressive acidic protein and postoperative immunotherapy in gastric cancer patients with total or proximal gastrectomy. Ann. Cancer Res. Ther. 1992; 1: 61
   Google Scholar
• Toris M., Katano M., Kimura Y. New approach to management of malignant ascites with a streptococcal preparation, OK-432: Improvement of host immunity and prolongation of survival. Surgery 1983; 93: 357
   PubMedGoogle Scholar
• Kato M., Hirose K., Hakozaki M. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol. Immunother. 1995; 40: 152
   PubMed Web of Science ®Google Scholar
• Hirose K., Zachariae C. O.C., Oppenheim J. J. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res. 1990; 9: 475
   PubMedGoogle Scholar
• Yang K. D., Stone R., Lee C. S. Effects of picibanil (OK-432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol. Immunother. 1992; 35: 277
   PubMed Web of Science ®Google Scholar
• Marucha P. T., Zeff R. A., Kreutzer D. L. Cytokine regulation of IL-1β gene expression in the human polymorphonuclear leukocyte. J. Immunol. 1990; 145: 2932–7
   PubMed Web of Science ®Google Scholar
• Cicco N. A., Lindemann A., Content J. Inducible production of interleukin-6 by human polymorphonuclear neutrophils: Role of granulocyte-macrophage colony stimulating factor and tumor necrosis factor-alpha. Blood 1990; 75: 2049
   PubMed Web of Science ®Google Scholar
• Bazzoni F., Cassatella M. A., Rossi F. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J. Exp. Med. 1991; 173: 771
   PubMed Web of Science ®Google Scholar
• Dubravec D. B., Spriggs D. R., Mannick J. A. Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor-α. Proc. Natl. Acad. Sci. USA 1990; 87: 6758
   PubMed Web of Science ®Google Scholar
• Lowenstein C. J., Snyder S. H. Nitric oxide, a novel biologic messenger. Cell 1992; 70: 705
   PubMed Web of Science ®Google Scholar
• Xie Q. W., Cho H. J., Calaycay J. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256: 225
   PubMed Web of Science ®Google Scholar
• Ding A. H., Nathan C. F., Stuehr D. J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J. Immunol. 1988; 141: 2407
   PubMed Web of Science ®Google Scholar
• Carreras M. C., Pargament G. A., Catz S. D. Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst of human neutrophils. FEBS. Letters 1994; 341: 65
   PubMed Web of Science ®Google Scholar
• Cui S., Reichner J. S., Mateo R. B. Activated murine macrophages induced apoptosis in tumor cells through nitric oxide-dependent or-independent mechanisms. Cancer Res. 1994; 54: 2462
   PubMed Web of Science ®Google Scholar
• Ioannidis I., Groot H. Cytotoxicity of nitric oxide in Fu5 rat hepatoma cells: evidence for co-operative action with hydrogen peroxide. Biochem. J. 1993; 296: 341
   PubMed Web of Science ®Google Scholar
• Asai K., Kato H., Kimura S. Induction of gene expression for nitric oxide synthase by immunomodulating drugs in RAW 264.7 murine macrophage cell line. Cancer Immunol. Immunother. 1996; 42: 275
   PubMed Web of Science ®Google Scholar
• Sato T., Midorikawa Y., Yamashita T. The neutrophil as an information transmitter in tumor inhibition by a streptococcal biological response modifier, OK-432. Cancer Immunol. Immunother. 1996; 43: 77
   PubMedGoogle Scholar
• Davis L. G., Dibner M. D., Batty J. F. Basic methods in molecular biology. Elsevier, New York 1986
   Google Scholar
• Chihara G., Hamuro J., Maeda Y. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. Cancer Res. 1970; 30: 2776
   PubMed Web of Science ®Google Scholar
• Okamura K., Suzuki M., Noda K. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. Cancer 1986; 58: 865
   PubMed Web of Science ®Google Scholar
• Inoue M., Kato H., Mukai S. Recombinant human granulocyte colony-stimulating factor augments cytotoxicity of OK-432-induced polymorphonuclear leukocytes. Int. J. Immunophar. 1994; 16: 19
   PubMedGoogle Scholar
• Kato H., Inoue M., Yamamura Y. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on cytotoxicity of PSK-induced peritoneal polymorphonuclear leukocytes (PMNs). Biotherapy 1992; 5: 177
   PubMedGoogle Scholar
• Lorsbach R. B., Murphy W. J., Lowenstein C. J. Expression of nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. J. Biol. Chem. 1993; 268: 1908
   PubMed Web of Science ®Google Scholar
• Stuehr D. J., Nathan C. F. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 1989; 169: 1543
   PubMed Web of Science ®Google Scholar
• Kwon N. S., Stuehr D. J., Nathan C. F. Inhibition of tumor cell ribonucleotide reductase by macropahge-derived nitric oxide. J. Exp. Med. 1991; 174: 761
   PubMed Web of Science ®Google Scholar
• Keller R., Geiges M., Keist R. L-arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Res. 1990; 50: 1421
   PubMedGoogle Scholar
• Takema M., Inaba K., Uno K. Effect of L-arginine on the retention of macrophage tumoricidal activity. J. Immunol. 1991; 146: 1928
   PubMed Web of Science ®Google Scholar
• Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB. J. 1992; 6: 3051
   PubMed Web of Science ®Google Scholar